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Oral Delivery of Bioencapsulated Exendin-4 Expressed in Chloroplasts Lowers
Blood Glucose Level in Mice and Stimulates Insulin Secretion in Beta-TC6 Cells
Abstract
Glucagon like peptide (GLP-1) increases insulin secretion but is rapidly degraded (half-life: 2 min in
circulation). GLP-1 analog, Exenatide (Byetta) has a longer half life (3.3–4 hrs) with potent insulinotropic
effects but requires cold storage, daily abdominal injections with short shelf life. Because diabetic
patients take >60,000 injections in their life time, alternative delivery methods are highly desired.
Exenatide is ideal for oral delivery because insulinotropism is glucose dependent, with reduced risk of
hypoglycemia even at higher doses. Therefore, exendin-4 (EX4) was expressed as a cholera toxin B
subunit (CTB)-fusion protein in tobacco chloroplasts to facilitate bioencapsulation within plant cells and
transmucosal delivery in the gut via GM1 receptors present in the intestinal epithelium. The transgene
integration was confirmed by PCR and Southern blot analysis. Expression level of CTB-EX4 reached up to
14.3% of total leaf protein (TLP). Lyophilization of leaf material increased therapeutic protein
concentration by 12–24 fold, extended their shelf life up to 15 months when stored at room temperature
and eliminated microbes present in fresh leaves. The pentameric structure, disulfide bonds and
functionality of CTB-EX4 were well preserved in lyophilized materials. Chloroplast derived CTB-EX4
showed increased insulin secretion similar to the commercial EX4 in beta-TC6, a mouse pancreatic cell
line. Even when 5,000-fold excess dose of CTB-EX4 was orally delivered, it stimulated insulin secretion
similar to the intraperitoneal injection of commercial EX4 but didn’t cause hypoglycemia in mice. Oral
delivery of the bioencapsulated EX4 should eliminate injections, increase patient compliance/
convenience and significantly lower their cost.
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Oral delivery of bioencapsulated exendin-4 expressed in
chloroplasts lowers blood glucose level in mice and stimulates
insulin secretion in beta-TC6 cells
Kwang-Chul Kwon, Ramya Nityanandam, James Stewart New, and Henry Daniell*
Department of Molecular Biology and Microbiology, College of Medicine, University of Central
Florida, Orlando, FL 32816-2364, USA

Summary
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Glucagon like peptide (GLP-1) increases insulin secretion but is rapidly degraded (half-life: 2 min
in circulation). GLP-1 analog, Exenatide (Byetta) has a longer half life (3.3–4 hrs) with potent
insulinotropic effects but requires cold storage, daily abdominal injections with short shelf life.
Because diabetic patients take >60,000 injections in their life time, alternative delivery methods
are highly desired. Exenatide is ideal for oral delivery because insulinotropism is glucose
dependent, with reduced risk of hypoglycemia even at higher doses. Therefore, exendin-4 (EX4)
was expressed as a cholera toxin B subunit (CTB)-fusion protein in tobacco chloroplasts to
facilitate bioencapsulation within plant cells and transmucosal delivery in the gut via GM1
receptors present in the intestinal epithelium. The transgene integration was confirmed by PCR
and Southern blot analysis. Expression level of CTB-EX4 reached up to 14.3% of total leaf protein
(TLP). Lyophilization of leaf material increased therapeutic protein concentration by 12–24 fold,
extended their shelf life up to 15 months when stored at room temperature and eliminated
microbes present in fresh leaves. The pentameric structure, disulfide bonds and functionality of
CTB-EX4 were well preserved in lyophilized materials. Chloroplast derived CTB-EX4 showed
increased insulin secretion similar to the commercial EX4 in beta-TC6, a mouse pancreatic cell
line. Even when 5,000-fold excess dose of CTB-EX4 was orally delivered, it stimulated insulin
secretion similar to the intraperitoneal injection of commercial EX4 but didn’t cause
hypoglycemia in mice. Oral delivery of the bioencapsulated EX4 should eliminate injections,
increase patient compliance/convenience and significantly lower their cost.
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Introduction
Peptides, as therapeutic agents, have several advantages in clinical applications due to their
low toxicity and high specificity (Bellmann-Sickert and Beck-Sickinger, 2010). Recently the
US Food and Drug Administration (FDA) approved several peptide drugs including
Enfuvirtide that inhibits HIV entry into cells, Exenatide that stimulates insulin secretion in
type 2 diabetes patients and several peptides for treatment of cancer (Bellmann-Sickert and
Beck-Sickinger, 2010). Despite these advantages, therapeutic peptides have several
limitations. They are highly prone to proteolytic degradation during storage or when used
for oral administration (McGregor, 2008) and require parenteral administration. In addition,
*
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these peptides need cold storage due to short shelf life after purification or chemical
synthesis. Moreover, repeated injections are often needed but this decreases patient
compliance (Hamman and Steenekamp, 2011). Therefore, there is a great need for
exploration of less expensive and patient-friendly drug delivery methods.

$watermark-text

Type 2 diabetes is caused by combination of beta cell dysfunction and insulin resistance
(Scheen, 2003). It is predominantly diagnosed in adults and responsible for 90–95% of the
existing diabetic cases (National diabetes fact sheet, 2011). Surplus production of hepatic
glucose and reduced uptake of glucose also contribute to excess blood sugar levels (Scheen,
2003). The type 2 diabetic patients exhibit belittled incretin effect, which requires insulin
secretion in response to high glucose in the blood (Scheen, 2003). Diabetes is a global rising
problem. According to the national diabetes fact sheet 2011, the total cost associated
annually for treatment and management of diabetes in the US is $116 billion whereas the
indirect costs associated with loss of work, disability and other factors was $58 billion
adding up the total cost to $174 billion. The treatment for diabetes includes either oral drugs
(small molecules) with or without insulin injections. Globally, the prevalence of diabetes is
estimated to escalate from 171 million in 2000 to 366 million in 2030 (Davidson, 2009),
which could double the associated costs. Diabetes is a major health and economic burden on
society (Wild et al., 2004) and therefore the cost of treatment of diabetes should be
addressed.

$watermark-text

GLP-1 is a peptide hormone secreted by the L cells of the intestine that stimulates the
secretion of insulin from the pancreas (Chia et al., 2005). It has been shown to play an
important role in increasing the beta cell mass and has potent antidiabetic effects associated
with weight loss (Baggio and Drucker, 2007). But GLP-1 has a very short half-life of less
than 2 min because it is degraded by the dipeptidyl peptidase IV (DPP-IV) serum enzyme
into biologically inactive form, thereby lowering the incretin action of the peptide (Kieffer et
al., 1995). Thus DPP-IV resistant GLP-1 analogs are needed for treatment of the type 2
diabetes.

$watermark-text

EX4 is a DPP-IV resistant analog of GLP-1 with higher binding efficacy to the mammalian
GLP-1 receptor than GLP-1 and functions as an effective agonist (Young et al., 1999). EX4
modulates the glucose level in a glucose dependent manner and increases the sensitivity to
insulin and has shown promising biological activities in vivo for treating type 2 diabetes
(Young et al., 1999). Exenatide, a synthetic EX4 is the first drug that carries out the function
of incretin to be approved by FDA for glycemic control, along with an oral antidiabetic
medication. Exenatide is used in injectable form and requires cold storage and sterility. In
addition, the requirement for multiple injections decreases patient compliance. Thus, there is
a need for alternative methods of production and delivery of EX4 or other therapeutic
proteins to reduce the cost and increase patient compliance.
Plants are ideal for expression of therapeutic proteins (Arntzen, 2008; Yusibov et al., 2011)
The use of plant chloroplasts to produce therapeutic proteins is emerging as an alternative
new technology in order to reduce their cost of production by elimination of purification,
cold storage, transportation, sterile delivery and by extension of their shelf life (Daniell,
2007). The chloroplast technology integrates transgenes into the chloroplast genome through
homologous recombination (Verma et al., 2008). The concept offers several advantages
including high levels of expression, proper folding, formation of disulfide bonds, and
oligomers, in addition to other post-translational modifications (Ruhlman et al., 2007;
Boyhan and Daniell, 2011; Daniell et al., 2009a). The maternal inheritance of chloroplast
genome and harvesting leaves before flowering offer important biological containment
strategies (Daniell, 2007). In addition, overcoming the transgene silencing and position
effect through site specific recombination minimize the number of events required for

Plant Biotechnol J. Author manuscript; available in PMC 2014 January 01.

Kwon et al.

Page 3

screening (Verma et al., 2008). A number of therapeutic proteins have been expressed in
plant chloroplasts including insulin like growth factor (Daniell et al., 2009b), interferon α2b
(Arlen et al., 2007), coagulation factor IX (Verma et al., 2010), proinsulin (Ruhlman et al.,
2007), antimicrobial peptides (Lee et al., 2011), human transforming growth factor-β3
(Gisby et al., 2011) vaccine antigens against viral, bacterial, and protozoan pathogens
(Davoodi-Semiromi et al., 2010; Fernández-San Millán et al., 2008; Koya et al., 2005).
However, oral delivery of transplastomic lyophilized leaf materials, stability of foreign
proteins after prolonged storage at room temperature, ability to deliver appropriate dosage,
consistency and preservation of the integrity of the heterologous protein, and microbial
contamination in plant materials, have not yet been investigated.

$watermark-text

In this project, we demonstrate that the chloroplast transformation system and
bioencapsulation within plant cells would be cost effective for the production and delivery
of functional EX4 for treatment of type 2 diabetes.

Results
Creation and characterization of CTB-EX4 transplastomic lines

$watermark-text
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CTB-EX4 fusion gene was constructed in the chloroplast transformation vector - pLD, with
a GPGP (Gly-Pro-Gly-Pro) hinge region to minimize steric hindrance of the fused EX4 and
furin cleavage site, RRKR (Arg-Arg-Lys-Arg), for its release into blood after the fusion
protein is internalized into epithelial cells (Figure 1a). EX4 is a 39-amino acid peptide
identified in the salivary gland of lizard, Heloderma suspectum and has 53% homology of
amino acid with GLP-1 but it has several distinct features from GLP-1. N-terminal sequence
(His-Gly-Glu) of EX4 (Figure 1a) is resistant to DPP-IV which rapidly cleaves the
corresponding GLP-1 sequence (His-Ala-Glu) (Doyle et al., 2003). In addition, C-terminal
9-amino acid sequence of EX4 (Figure 1a), which is absent from GLP-1, showed biological
importance. Its truncated form, EX4 (1–30), has 10 times less binding affinity to GLP-1
receptor, which is similar to that of GLP-1 (Doyle et al., 2003). Many of substrate sequences
to endopeptidase are present in GLP-1 but not in EX4 (Hupe-Sodmann et al., 1995). These
features make the EX4 5,500 times more potent GLP-1 receptor agonist than GLP-1
(Davidson, 2009). Therefore, EX4 was chosen for expression in plant chloroplasts. The
fusion gene was driven by the psbA promoter and 5′ untranslated region (UTR) to increase
expression and the transcript was stabilized by the psbA 3′ UTR. The cloned CTB-EX4
fusion gene into the chloroplast vector was fully sequenced before bombardment. The
putative transplastomic lines were confirmed for transgene integration using the primer sets
which were able to anneal specifically to complementary sequences of transgene cassette
and the chloroplast genome. PCR results showed products of expected sizes as a result of
amplification for the defined region with those primers, 1.65 kb with 3P/3M and 2.1 kb with
5P/2M (Figure 1b). The site specific integration of the CTB-EX4 gene was further
confirmed using Southern blot analysis, by probing with the trnI and trnA flanking
sequence. Three Hind III restricted independent transplastomic lines showed distinct
hybridizing fragments of 9.77 kb (Figure 1c) but not the 7.67 kb fragment from wild type.
Thus Southern blot analysis confirmed the site specific and stable integration of the
transgenes into the chloroplast genome and homoplasmy.
Characterization of CTB-EX4 fusion protein expressed in chloroplasts
To investigate proper translation of the two genes within chloroplasts, specific antibodies
against CTB or EX4 were used. Both of the antibodies detected the expected fusion protein
of correct size, with no cross-reacting proteins from untransformed plants. As expected, the
detected band pattern was identical to each other (Figure 2a, b). In addition, there was no
cross detection of CTB standard proteins by anti-EX4 antibody (Figure 2b). Each CTB
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monomer has an intramolecular disulfide bond. Extensive interactions between monomers
(hydrogen bonds, salt bridges, and hydrophobic interactions) are responsible for the stable
pentameric structure of CTB (Sánchez and Holmgren, 2008). But this integrity was
disrupted when reducing agents were included in the extraction buffer (Figure 2a, b) in
which much more monomeric form of CTB-EX4 was observed, when compared with the
extraction without the reducing agent. Moreover, much less of the fusion protein was
detected in the soluble fraction (Figure 2a, b). The expression level of the fusion protein was
measured quantitatively using densitometry with known amount of CTB protein to generate
standard curve (Figure S1) at different time points. The range of expression varied between
7.6% and 14.3% of TLP (Figure 2c). When the ability of CTB-EX4 fusion protein to bind to
the GM1 receptor was evaluated by GM1 ELISA, the absorbance values were similar to the
CTB postive control. This indicates that there was proper folding and disulfide bond
formation that are required for the formation of the pentameric structure of CTB-EX4
(Figure 2d).
Stability, folding, dosage, microbes in lyophilized materials after prolonged storage

$watermark-text
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In this study, lyophilized leaf material (6.26 mg of CTB-EX4/g) was used to deliver
appropriate dose of CTB-EX4 by oral gavage in mice. The content of CTB-EX4 increased
12.5 fold when compared to fresh leaf material (0.5 mg of CTB-EX4/g) (Figure 3a) and
significant difference in CTB-EX4 intensity was also observed with equal loading of
proteins (equal weight) from fresh and lyophilized plant materials, in a serial dilution
(Figure 3b), further confirming quantitative studies. The functionality of the lyophilized
fusion protein was confirmed using GM1 ELISA and western blot assays. In the
immunoblots with the separation range of 10–250 kDa, use of specific polyclonal antibodies
against CTB, EX4, and PA did not detect any cleaved fragments for each lyophilized protein
in, providing evidence for their stability. The comparable absorbance of lyophilized CTBEX4 to CTB standard was detected (Figure 2d) and oligomeric forms of CTB were also
detected (Figure 3b). These results indicate that lyophilization does not affect the assembly
of CTB pentamer. In this study, lyophilized leaves stored up to 4 months at room
temperature did not show any degraded CTB-EX4 protein. To investigate long-term stability
of CTB-EX4 further, 10 month-old lyophilized leaf material was compared with fresh leaves
in different conditions using western blots. Detected band patterns between fresh and
lyophilized protein samples were identical, including formation of pentamers or oligomers
(Figure 3c, d). Furthermore, the relative band intensity between CTB-EX4 monomers of
lyophilized samples gradually increased with denaturation (by boiling and/or addition of
DTT, Figure 3d). Relative decrease of the monomer intensity was 100 (+ and +, boiling and
DTT, respectively), 66 (− and +), 40 (+ and −), and 7.8 % (− and −) (Figure 3d). This
demonstrated that pentameric structure of CTB-EX4 can be stably maintained in lyophilized
state for a long time at room temperature.
To evaluate stability of therapeutic proteins after long-term storage of lyophilized materials
at room temperature, transplastomic lettuce expressing the protective antigen (PA) from
Bacillus anthracis and CTB fused proinsulin (CTB-Pins) were investigated. The reason for
investigating stability of other proteins unrelated to this project is to evaluate the
reproducibility of this concept and to evaluate stability of much larger size proteins (EX4 is
~4.2 kDa whereas the Anthrax protective antigen is ~83 kDa). The soluble PA is stable up to
6 months of storage at room temperature in lyophilized leaves with no apparent cleaved
products similar to fresh material (Figure 3e). Further study showed that PA is stable in
lyophilized lettuce stored at room temperature for more than 15 months (data not shown).
The duration of lyophilization did not affect the stability of PA (Figure 3f) but optimal
dehydration was achieved after 72 hrs dehydration. Concentration of both PA and CTB-Pins
increased 24 fold in lyophilized leaves when compared to fresh transplastomic materials
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(Figure 3h). The fold increase of total leaf proteins was also similar to that of the antigens
when compared to fresh material (Figure 3g). Much more intense band against PA was
observed over the fresh material in western blots when equal mass of samples were loaded
(Figure 3i), further confirming quantitative studies.

$watermark-text

Bacterial contamination was investigated between fresh and lyophilized materials to
facilitate the safe oral delivery. For comparison, commercially available freeze-dried alfalfa
was used as control. While fresh lettuce leaves contained up to ~6,000 cfu/g microbes,
lyophilized leaves expressing various foreign proteins had no detectable microbes, when
plated on different growth media (Figure 3j). These investigations show that highly
concentrated therapeutic peptides or proteins could be delivered orally and safely, when the
lyophilized leaf material is used in capsules (Figure 3k).
Purification and characterization of transplastomic EX4

$watermark-text

The CTB-EX4 fusion protein was purified with the anti-CTB antibody conjugated to protein
A beads. The immunoblot assay against purified CTB-EX4 showed that the first elution
fraction contained the highest amount of fusion protein and densitometric analysis of the
first elution of purification revealed 73% purity (Figure 4a). Silver stained gel showed a
prominent single band, which corresponded to the CTB-EX4 band in the western blot
(Figure 4b). Then furin cleavage assay was performed with the purified fusion protein to
check if the oral delivery of proteins would result in cleavage of transplastomic proteins by
the furin enzyme, which is present ubiquitously in all cell and tissue types in the body
(Limaye et al., 2006). The furin treated sample revealed the presence of an additional
polypeptide at ~12.7 kDa, which represents the size of CTB monomer subunit (including 8
amino acids for the hinge and furin cleavage site) without EX4 fusion (Figure 4c, d)
indicating the furin cleavage site introduced in the construct was functional. The silver stain
revealed two cleavage products, one at ~12.7 kDa representing the same size of cleaved
CTB product as in Figure 4c and a faint band at ~4.2 kDa representing the EX4 monomer
(Figure 4d). These results confirmed accessibility of furin to its cleavage site to release EX4
after the fusion protein is internalized, by binding to GM1 receptor present on the intestinal
epithelium cell surface.
In vitro beta-TC6 pancreatic cell line assay to evaluate insulin secretion

$watermark-text

For functional evaluation of CTB-EX4, purified fusion protein was incubated with beta-TC6
cells, mouse pancreatic cell line harboring GLP-1 receptor on their surface. The role of the
receptor is to amplify glucose-dependent insulin secretion. In a previous report, beta-TC6
cells increased insulin secretion in response to glucose concentration in a range from 0 to 20
mM. The insulin secretion was further enhanced when EX4 was added within the range of
glucose (Masure et al., 2005). In this study, single glucose concentration (10 mM) was
chosen to investigate the enhancement of insulin secretion by increasing the concentration of
CTB-EX4. Direct comparison of commercial EX4 with purified CTB-EX4 for insulin
secretion was inadequate due to a different molecular weight and a fusion protein.
Therefore, the amount of secreted insulin was compared by increasing concentration of each
protein in a dose dependent manner. Indeed beta cells treated with different levels of purity
of CTB-EX4 (crude plant extract, partial and total purification) were evaluated in 88 wells
of the insulin ELISA detection kit for optimization and several independent investigations.
We compared insulin secretion between commercial EX4 and purified CTB-EX4 at three
different concentrations using 88 wells of insulin detection kit. All independent
investigations confirmed that purified CTB-EX4 showed insulin secretion activity similar to
commercial EX4. For control PBS was used instead of CTB alone because commercial CTB
is purified from E. coli and it exists as a monomer. But chloroplast-derived CTB-EX4 exists
in pentameric form (required for GM1 binding) or other oligomeric forms as seen in Figure
Plant Biotechnol J. Author manuscript; available in PMC 2014 January 01.
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2a and b. Therefore, commercial CTB does not serve as an appropriate control. Insulin
secretion reached its maximum at the concentration of 4X when treated with commercially
available EX4 peptide, which is consistent with a previous report (Baggio et al., 2004).
Likewise, purified CTB-EX4 also increased insulin secretion in a concentration dependent
manner (Figure 4e). Therefore, this result indicates similar functionality of EX4 when fused
with CTB expressed in plant chloroplasts or when EX4 was chemically synthesized.
Oral delivery of lyophilized CTB-EX4 transplastomic leaves to mice lowered blood glucose
level

$watermark-text
$watermark-text

In order to investigate the potential for lowering blood glucose level after oral delivery of
lyophilized CTB-EX4 leaf material, blood glucose level was tested in mice after glucose
spike by intraperitoneal injection. In three previous independent tests, CTB-EX4 showed its
function of lowering glucose level at 90 min after oral gavage, even without glucose spike
(data not shown). For evaluation of orally delivered lyophilized CTB-EX4 effect on glucose
level, blood glucose levels were measured in mice sera at different time points using 288
glucose test strips for optimizing this system, with or without glucose spike and overnight
fasting. Glucose measurements were made 2 or 3 times for each mouse, for a total of 288
evaluations of blood glucose levels in mouse sera. Administered dosage was calculated for
each method. 2.39 × 10−6 μmole of EX4 per mouse (0.01 μg/4.19 kDa, MW of EX4) was
used for i.p. injection, while 1.2 × 10−2 μmol of lyophilized EX4-CTB per mouse (208.5 μg/
17.2 kDa, MW of CTB-EX4) was delivered orally. To evaluate glucose lowering potential
by CTB-EX4, blood glucose level of mice was spiked intraperitoneally at 60 min after oral
gavage. Glucose lowering effect of CTB-EX4 reached maximum up to 24.8% reduction at
t=90 (Figure 5a). As the duration after oral gavage increased, the glucose lowering effect
became smaller (17.3% at t=120, and 10.1% at t=150) then finally came down to similar
level to control group at t=180 (Figure 5a), due to the normal functional pancreas. To
compare the potency of chloroplast derived CTB-EX4 with synthetic EX4 peptide in terms
of glucose lowering effect, mice were subject to same procedure as in Figure 5a except for
i.p. injection of EX4 peptide instead of oral gavage of CTB-EX4 plant material. Similar
glucose lowering effect (21.8% reduction) was observed at t=90 as oral gavage (Figure 5b).
Taken together, oral administration of lyophilized CTB-EX4 fusion protein produced in
plant chloroplast functions similar to commercial purified EX4 peptide.

Discussion
$watermark-text

Type 2 diabetes affects a vast majority of the global population and requires cost effective
treatment, which otherwise poses the threat of becoming a pandemic (National diabetes fact
sheet, 2011). Exenatide, an injectable insulinotropic agent demonstrates appreciable
antidiabetic effects in clinical use among type 2 diabetes patients (Lovshin and Drucker,
2009; Riddle et al., 2006) but requires cold storage and injections. This kind of subcutaneous
injection in the abdomen is very inconvenient for patient because injection sites should be
cleaned with alcohol before use and/or rotated to avoid or minimize skin irritation (Barnhart
et al., 2011). In this study, we report the expression of CTB fused EX4 in chloroplast and its
functionality comparable to commercial EX4. This system has several cost saving
advantages associated with production, purification, storage and transportation when
compared to current methods of production..
Success in using freeze-dried material will depend upon the stability of foreign proteins,
ability to deliver appropriate dosage and consistency. It is crucial for freeze-dried and stored
materials to preserve the integrity of the heterologous fusion protein because efficient
delivery of the intact protein to the gut-associated lymphoid tissue (GALT) requires proper
folding and assembly (e.g. CTB pentamers to bind GM1) (Boyhan and Daneill, 2011;
Verma et al., 2010; Limaye et al., 2006). In this study, we have shown that fresh and
Plant Biotechnol J. Author manuscript; available in PMC 2014 January 01.
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lyophilized materials form CTB pentamers and the protein profile of monomers, dimers or
pentamers is identical. In the preparation of transplastomic material for oral delivery,
transformed leaves must be powdered and packaged into capsules. Leaves from fully-grown
plants were harvested, freeze-dried and lyophilized leaves were powdered in a grinder and
stored at room temperature in moisture free containers containing silica gel. Machines are
now commercially available for lyophilization and preparation of capsules with desired
particle sizes.

$watermark-text

In our hands freeze-dried plant tissues containing vaccine antigens without CTB-fusion
proteins were stable for more than 15 months when stored at room temperature at 25°C.
CTB-EX4 was stable in lyophilized tissues throughout the duration of this study. CTBfusion proteins should be more stable because of formation of pentamers or aggregates,
thereby protecting them from proteolytic degradation. While there are differences in
expression levels based on leaf age or developmental stage, therapeutic protein dose should
be determined in each batch of dehydrated ground powder leaves by ELISA or other
quantitative methods. Although the increase in concentration of proteins expressed in plants
during lyophilization is anticipated, this study reports stability, folding and functionality of
therapeutic proteins bioencapsulated in plant cells. Long-term storage at room temperature,
elimination of cold chain and purification steps offer the best opportunities to advance lowcost plant-derived therapeutic proteins.

$watermark-text
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Nature’s Way has been marketing alfalfa capsules as nutrition supplement for several
decades, illustrating the ability to eliminate pathogenic microbial threats in freeze-dried
leaves. The application of freeze-drying as a source of microbial reduction was therefore
investigated. Resident microbes of freshly harvested leaves were examined, and the impact
of lyophilization on viable colony forming units was tested using standard microbiological
assays for pathogenic bacteria, coliforms, yeast, and molds. For comparison, commercially
available fresh and freeze-dried alfalfa was tested. While fresh lettuce leaves contained up to
6,000 cfu/g of microbes, lyophilized leaves expressing various foreign proteins had no
detectable microbes when plated on different growth media. Therefore, the lyophilization
process killed microbes present in fresh leaves. Although lyophilization is used for longterm storage of some bacteria, such freeze drying process requires lyoprotective media
components including skim milk, sucrose, trehalose, fetal calf serum, BSA, etc. and would
require low temperature for long-term storage (Heckly, 1985). However, in this study, no
lyoprotective component was used and the lyophilized transplastomic plants were stored at
room temperature up to 15 months without any harmful effect on their proteins. Moreover,
the stability of the proteins expressed in transplastomic plants was unaffected even after 72
hrs of lyophilization whereas bacterial lyophilization is performed for a shorter duration.
Therefore, we believe that differences in the process of lyophilization without any protective
components and long duration of lyophilization should have eliminated microbes from
lyophilized transplastomic plants.
For considerations on safety of oral delivery of peptides, several important questions must
be considered. Multiple doses of daily use of Exenatide has been already approved by the
US FDA for the treatment of type 2 diabetes (Lam and See, 2006), and CTB was also
approved as adjuvant for human vaccines or as a vaccine antigen (Ryan and Calderwood,
2000; Reed et al., 2009). Because CTB is immunogenic, there could be potential concerns
on fusion of these two peptides resulting in development of antibody against EX4. Two
recent articles (Odumosu et al., 2011a; Odumosu et al., 2011b) investigated the mechanism
of CTB fusion proteins and showed immune suppression of proteins tethered to CTB. For
example, CTB-proinsulin suppressed dendritic cell (DC) activation by up-regulating Toll
like receptor 2 (TLR-2). Furthermore, fusion of CTB to proinsulin was essential for
enhancement of immune suppression, as co-delivery of CTB and insulin did not
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significantly inhibit biosynthesis of co-stimulatory factors in dendritic cells (Odumosu et al.,
2011a). Likewise, another autoantigen glutamic acid decarboxylase fused with CTB strongly
inhibited dendritic cell maturation through down-regulation of major co-stimulatory factors
and inflammatory cytokine biosynthesis (Odumosu et al., 2011b). These results show that
CTB–fusion proteins enhance immunosuppressive T lymphocytes and don’t promote
development of immunity of tethered proteins. Oral administration of CTB-linked
autoantigens has been shown to induce tolerance by suppressing development of immune
response in several allergic or autoimmune diseases (Ruhlman et al., 2007; Verma et al.,
2010; Sun et al., 2010). Moreover, immunological tolerance of CTB-linked-antigen delivery
in human clinical studies (phase I/phase II) has already been reported. Behcet’s disease is an
autoimmune eye disease caused by abnormal T cell reactivity to a specific peptide (BD
peptide). In this CTB-based immunotherapy, there was no evidence for antibody production
when CTB-BD peptide was orally delivered for 12~16 weeks and some patients were free of
this disease up to 24 months (Stanford et al., 2004). Several studies described above show
that mucosal tolerance conferred by CTB is associated with regulatory T cells that secrete
immunosuppressive cytokines, transforming growth factor (TGF-β) or interleukin 10 (Sun et
al., 2010; Ma and Jevnikar, 2012).
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Another reason for not developing antibody is probably because these are native proteins
(autoantigens) and a furin (ubiquitous protease present in all cell/tissue types) cleavage site
was engineered between the CTB and the fusion protein for prompt cleavage soon after
transmucosal delivery. In contrast to autoantigens, EX4 is a heterologous therapeutic peptide
with 53% amino acid homology to human GLP-1. Even though EX4 showed the anti-EX4
antibody formation during the 30-week EX4 clinical trial (Kendall et al., 2005), there are no
reports of any adverse immune response from patients since it was released to the clinic in
2005, with twice or thrice daily injections. According to the latest FDA safety update for
Exenatide prescribed to more than 6.6 million patients (FDA drug safety information, 2009),
no adverse immune response in type II patients routinely receiving EX4 was reported.
However, the Byetta (Exenatide) Summary of Product Characteristics by Eli Lilly (updated
on the eMC on July 5, 2012) reported antibody titres against Exenatide diminished over time
and remained low through 82 weeks in most patients who developed antibodies. As
discussed above, CTB conjugated autoantigens have been shown to suppress rather than
stimulate the immune system, leading the immune system to tolerate the autoantigens.
Therefore, it is anticipated that conjugation of EX4 to CTB should help develop tolerance
rather than stimulate immune response. There are several other advantages for using CTB as
a transmucosal carrier. Large mucosal area (approximately 1.8 m2 ~ 2.7 m2 against body
weight) (Wilson, 1967) could maximize CTB binding to human intestinal epithelium
(15,000 binding sites per cell) (Holmgren et al., 1975). The rapid turnover rate of cellassociated GM1 receptor on the epithelial cell (Fishman et al., 1983) is yet another
advantage. However, if there is a need to investigate non-receptor mediated delivery system,
protein transduction domains (PTD) are ideal due to their ability to carry cargo across the
plasma membrane (Wadia and Dowdy, 2002).
The beta-TC6 cell line, a mouse pancreatic beta cell line was used for evaluation of the
functionality of chloroplast derived CTB-EX4 because it exhibits the property of glucose
mediated insulin secretion, triggered by binding of GLP-1 to its receptor on cell surface
(Hohmeier and Newgard, 2004; Skelin et al., 2010). This in vitro study revealed that the
transplastomic protein increased the insulin secretion from the pancreatic beta cell line. The
insulin secretion was dose-dependent similar to the commercially available EX4.
Actual goal of this study is to deliver bioencapsulated therapeutic proteins orally with no
need for any purification because purified EX4 is already available in the clinic for
injectable delivery system. Therefore, animal studies were carried out to investigate the in
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vivo functionality of orally administered lyophilized EX4. In the animal studies,
transplastomic CTB-EX4 further confirmed its ability to reduce blood glucose level similar
to injections of commercial EX4 (Figure 5). The mouse strain (C57Bl/6) was chosen based
on previous studies on EX4 injections (Stoffers et al., 2000). Non-obese diabetic mouse
model can’t be used for this study because insulin secretion is impaired in this mouse model.
Other mouse models used for type 2 (spontaneous, chemically induced, surgical, transgenic/
knock-out diabetic mice) are only suitable for long-term evaluation studies (Srinivasan and
Ramarao, 2007). So blood glucose level of mice was intentionally spiked to mimic diabetic
symptoms in order to explore the efficacy of orally delivered EX4 on hyperglycemic
condition. The amount of EX4 administered orally to mouse was about 5,000 times higher
than that of i.p. injections. It has been well known that EX4 lowers blood glucose levels by
increasing insulin secretion from beta cell in a glucose dependent manner, contrasting other
insulin secretagogues (eg, sulfonylureas) by which insulin secretion is increased regardless
of glucose concentrations (Kolterman et al., 2003). So the concern about the risk of
hypoglycemia can be eliminated even when excess amount of EX4 was administered, owing
to the glucose dependent insulinotropic mechanism of EX4. This is one of reasons why we
chose the EX4 to be expressed in an encapsulated form using chloroplasts for oral delivery.
Actually, there was no detrimental effect on mice even when we delivered the 5,000 times
higher dose of CTB-EX4 over i.p. injection. In a previously reported investigation (Young et
al., 1999), the glycemic control potency of EX4 was tested with diabetic db/db mice in a
range from 0.001 μg to 10 μg of EX4 per mouse. There was no harmful effect on mice even
in higher dose injections (1 and 10 μg) in which plasma glucose was rather maintained at
stably lowered level for a longer period than lower dosages (0.001, 0.01, and 0.1 μg). In
addition, all of the bioencapsulated CTB-EX4 will not be delivered into the circulatory
system due to a direct passage of gastrointestinal tract and degradation of nonbioencapsulated CTB-EX4 in stomach. Therefore, lyophilized and bioencapsulated CTBEX4 system could provide a convenient and cost-effective delivery method as an alternative
way to replace current injectable system for the treatment of type II diabetes, without
causing a severe side effect such as hypoglycemia.
The current cost of Exenatide for daily use (twice daily) exceeding several thousand dollars
annually is not available for a large population in developing countries, earning <$2/day
(Bond, 2006). But producing Exenatide in the lettuce chloroplast transformation system
should provide a solution to the existing problem and would significantly lower the cost of
incretin treatment for type 2 diabetes. So the idea presented in this study is intriguing and
potentially could benefit the lives and economy of people suffering from type 2 diabetes
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Experimental procedures
Vector construction, transgene integration, regeneration, and evaluation of transplastomic
plants
The CTB-EX4 chimeric gene (465 bp) was synthesized with specific primer sets. One
forward primer: DV42 (5′-TTCATATGACACCTCAAAATATTACTGATT-3′) and three
reverse primers: R1-EX4 (5′CATTTGTTTAGATAAATCAGAAGTGAAAGTACCTTCAC
CATGACGTTTACGCCGGGGCCC-3′), R2-EX4 (5′CCGTTTTTTAACCATTCAATGAATA
AACGTACAGCTTCTTCTTCCATTTGTTTAGATAAA-3′), R3-EX4 (5′AGTTCTAGATCA
AGAAGGAGGAGGAGCACCAGAAGAAGGACCACCGTTTTTTAACCATTC-3′) were
used. The three reverse primers had overlapping sequence for each other to elongate the
coding sequence. The PCR amplified and sequence-confirmed fragment was cloned into the
chloroplast transformation vector, pLD. Delivery of chloroplast vector, regeneration,
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evaluation, and quantification of transplastomic lines were done according to the previously
published methods (Verma et al., 2008). Immunoblot analyses were carried out with rabbit
anti-CTB polyclonal antibody (GeneWay), rabbit anti-EX4 polyclonal antibody (Abcam),
and anti-PA polyclonal antibody (Ruhlman et al., 2010). The binding assay of functional
pentameric form of CTB-EX4 to GM1 ganglioside receptor was carried out as described
previously (Limaye et al., 2006)
Lyophilization

$watermark-text

Crumbled and frozen samples were transported to the lyophilizer on liquid nitrogen and
treated for varying durations of 24, 48 and 72 hrs. Optimization based on percentage of
dehydration was measured through relative gravimetric analysis. Lyophilization was carried
out with the aid of VirTis BenchTop 6K freeze dryer system in vacuum at −52° C at 0.036
mBar. The lyophilized leaf materials were ground in a coffee grinder (Hamilton Beach) at
maximum speed for 2 min (pulse on 10 sec and off 30 sec) and sieved using mesh (Sigma,
size: 100). After that, fine powder was stored in capsules under moisture-free condition at
room temperature with silica gel.
Evaluation of microbes
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Fresh and lyophilized materials were ground under aseptic conditions, mixed with peptonesaline diluents for serial dilutions to obtain colony count. Nutrient Broth Agar or LuriaBertani Broth Agar were used for microbial growth for 48–72 hr at 37°C. Colony forming
unit (CFU) was obtained with means and standard deviations from two repeats of
independent experiments.
Purification of CTB-EX4, furin cleavage and silver staining
To purify CTB-EX4 fusion proteins, pierce crosslink IP kit (Thermo Scientific) was used
according to the manufacturer’s protocol. The eluted fractions were dialyzed against PBS 3
times, aliquoted and stored at −20°C. Furin cleavage assay was performed as previously
described (Munck et al., 1999). Released CTB fragments and EX4 peptides were detected
via immunoblot using anti-CTB polyclonal antibody and silver stain (Boyhan and Daniell,
2011), respectively after resolution in Tricine-SDS-PAGE gel (Schägger, 2006).
In vitro cell culture assay

$watermark-text

The mouse pancreatic cell line, beta-TC6 was cultured in DMEM (ATCC) medium
supplemented with 15% heat inactivated fetal bovine serum, 100 U/ml penicillin and 100 U/
ml streptomycin at 37°C under 5% CO2 condition. The beta-TC6 cells were harvested at 70–
80% confluence and incubated in glucose-free Krebs Ringer bicarbonate buffer for 1 hr at
37°C. The buffer was then removed and cells were incubated in Krebs-Ringer bicarbonate
buffer with the various concentrations of purified CTB-EX4, commercial EX4 (California
Peptide Research) and glucose (10 mM) for 45 min at 37°C. PBS was used as the negative
control. The amount of insulin secreted into the supernatant was determined using the mouse
insulin ELISA kit (Crystal Chem).
Animal study for evaluation of lowering effect of CTB-EX4
Ten-week-old female mice (C57BL/6) were purchased from The Jackson Laboratory. Mice
were housed in UCF animal facility under controlled humidity and temperature conditions.
All animal studies were performed according to ethical standards and protocols approved by
the UCF Institutional Animal Care Use Committee (IACUC). The fine powder of the
lyophilized leaf material expressing CTB-EX4 was resuspended in a ratio of 100 mg to 800
μl of sterilized PBS. Then 300 ul out of 900 ul of resuspended solution was given to each
mouse (1.2 × 10−2 μmol of EX4-CTB/mouse, 15 weeks old). Commercial EX4 was
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resuspended in PBS and sterilized using 0.2 μm syringe filter. Mice were given 200 ul of
PBS containing EX4 (0.01 μg, 2.39 × 10−6 μmole of EX4/mouse) and PBS only as control.
For glucose spike in mice, glucose (2g/kg) was administered intraperitoneally. Blood was
collected from tail vein at 30, 90, 120, 150, and 180 min after or 30 min before oral gavage
or i.p. injection of commercial EX4. Glucose levels were measured using Accu-Chek
(Roche).
Statistics
Single factor ANOVA was used for statistical evaluation of data. Differences with P < 0.05
were considered significant. Data are presented as the mean ± SD.

$watermark-text

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.

Evaluation of transgene integration. (a) Schematic representation of the flanking sequence
probe (0.81 kb) and expected products of the untransformed and transplastomic tobacco
chloroplast genome when digested with HindIII (H). Southern blot probe was generated
using BamHI (B) and BglII (B′). Primers used for transgene amplification are represented
by arrows. Amino acid sequence indicates the hinge, furin cleavage site, and EX4 (bold
letter). Asterisk represents resistant amino acid against DPP-IV. C-terminal 9-amino acid is
represented by dotted line. (b) The amplification of genomic DNA fragment with 3P/3M and
5P/2M primer sets to check transgene integration. M, DNA size marker; WT,
untransformed; #5, 6, and 9, transplastomic lines; Ve, CTB-EX4 containing pLD vector. (c)
Southern blot analysis of CTB-EX4 transplastomic lines showing homoplasmy.
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Figure 2.
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Quantification and functional evaluation of CTB-EX4. Western blot analysis of total leaf
homogenate (H, 5 μg) and soluble (S, 5 μg) protein probed with anti-CTB (a) or anti-EX4
(b) antibodies. Lane 1, 6.25; 2, 12.5; 3, 25 ng of purified cholera toxin B subunit; +, with
DTT; −, without DTT; #6 and 9, CTB-EX4 transplastomic lines; WT, untransformed. (c)
Percentage of CTB-EX4 in the total leaf protein from mature leaves at different harvesting
time. (d) GM1 ELISA assay for evaluation of CTB-EX4 pentamer assembly. CTB, positive
control (10 ng); F, fresh leaf; L, lyophilized CTB-EX4 transplastomic plant extracts (5 μg of
total leaf protein), respectively; WT, untransformed total leaf protein (5 μg), BSA, negative
control. Data shown are means ± SD of three independent experiments.
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Figure 3.
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Lyophilization and characterization. (a) Amount of CTB-EX4 protein in fresh (F) and
lyophilized (L) leaves. (b) Western blot analysis of fresh and lyophilized leaves expressing
CTB-EX4. Equal quantity (50 mg) of fresh and lyophilized material was extracted in same
volume (300 μl) of extraction buffer. Samples were loaded in a serial dilution as indicated.
Western blot analysis with anti-CTB (c) and anti-EX4 (d) polyclonal antibody to evaluate
long-term stability of lyophilized CTB-EX4 after storage at room temperature for 10
months. F, fresh leaf; L, 10-month old lyophilized leaf. Total leaf protein (5 μg) was loaded
in each lane. CTB, Positive or negative control (20 ng). Samples were incubated for 10 min
with DTT (100 mM) or boiled for 2 minutes. (e) Western blot analysis to evaluate stability
of PA in lyophilized lettuce leaves after storage at room temperature for 2 (1), 4 (2), and 6
(3) months. PA, standard (100 ng), WT, untransformed lettuce. Total soluble protein (3 μg)
was loaded in each lane. (f) Antigen stability after 3 months of storage, and lyophilization
for different durations: (1) 24, (2) 48 and (3) 72 hrs. Fold increase of total protein (g) and
specific antigen (h) after lyophilization. PA, lettuce transplastomic plant expressing PA;
CTB-Pins, lettuce transplastomic plant expressing CTB-Proinsulin; white bar, fresh
material; grey bar, lyophilized material. (i) Western blot analysis of fresh (F) and lyophilized
(L) leaves expressing PA. Total soluble protein (10 μl) was loaded after equal quantity (50
mg) was extracted in same volume (300 μl) of extraction buffer. (j) Microbial burden of
leaves expressing PA. 1, fresh leaf; 2, lyophilized leaf; 3, commercially available freezedried alfalfa capsules. (k) Simplified diagram of capsulation of lyophilized transplastomic
leaf material. Data shown are means ± SD of three independent experiments.
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Figure 4.
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Purification of CTB-EX4 and pancreatic cell line assay. Western blot (a) and silver staining
(b) of purified CTB-EX4. 1–3, CTB standard proteins of 12.5, 25, and 37.5 ng; 4, wild type
total leaf protein (5 μg); 5, soluble fraction of CTB-EX4 before purification (5 μg); 6,
soluble fraction of CTB-EX4 after purification (5 μg); 7–9, washed fractions; 10–12, elution
fractions. (c, d) Furin cleavage assay of purified CTB-EX4. CTB, standard (25 ng); −F,
without furin; +F, with furin; M, protein size marker; M′, ultra-low range protein size
marker; arrow head, cleaved CTB (12.7 kDa); arrow, cleaved EX4 (4.2 kDa); dots and
numbers, locations of monomer and oligomers of CTB-EX4. Proteins were resolved on 12%
(c) and 16% (d) of Tricine-SDS-PAGE. (e) Mouse pancreatic cell line assay. Commercial
EX4 (1X =5 nM) and partially purified CTB-EX4 (1X = 32 nM, concentration based on the
molecular weight of the CTB) were added to beta-TC6 cells. The graph was normalized to
PBS value which was used as a negative control. Insulin secretion was compared at three
different concentrations in each group, with duplicate samples, using 88 wells of insulin
detection kit. Data shown are means ± SD (n=6).
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Figure 5.

Evaluation of functionality of CTB-EX4 in mice after oral gavage or injection. Glucose (2g/
kg body weight) was injected intraperitoneally at t=60 (arrows). (a) Mice were orally
gavaged with lyophilized untransformed (WT) and CTB-EX4 plant leaf materials (EX4) at
t=0. One outlier was removed from control group because of no glucose spike at t=90. (b)
Mice were given i.p. injection of PBS (200 μl) and commercial EX4 resuspended in PBS
(0.01 μg in 200 μl) at t=0. Glucose measurements were made 2 or 3 times for each mouse,
for a total of 288 evaluations of blood glucose levels in mouse sera. Single factor ANOVA
was performed to test significant difference between groups statistically. *P < 0.05, **P <
0.01.
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